Skip Navigation

Publication Detail

Title: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk.

Authors: Shen, Jing; Gammon, Marilie D; Terry, Mary Beth; Teitelbaum, Susan L; Neugut, Alfred I; Santella, Regina M

Published In Breast Cancer Res, (2006)

Abstract: The association between use of nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk remains unclear. Inconsistencies in previously reported findings may be partly due to differences in expression of cyclooxygenase (COX)-2. We hypothesized that genetic polymorphisms (COX-2 .926, COX-2 .5209, and COX-2 .8473) may reduce overall breast cancer risk or risk for subtypes of breast cancer by modulating the inflammatory response and may interact with aspirin or any NSAID use.We conducted a population-based, case-control study in which we genotyped 1,067 breast cancer cases and 1,110 control individuals included in the Long Island Breast Cancer Study Project.No major effects of the three COX-2 variant alleles on breast cancer risk were found. A total of eight distinct haplotypes and 18 diplotypes were observed in the population. Overall, no significant associations between COX-2 haplotypes/diplotypes and breast cancer risk were observed. Among women who used aspirin or any NSAID there was little evidence for an interaction with the at-risk COX-2 genotypes, with one exception. Among women with hormone receptor positive breast cancer, the reduced risk for any NSAID use was only evident among those who had at least one variant C allele of COX-2 .8473 (odds ratio = 0.7, 95% confidence interval = 0.5 to 1.0; P for the interaction = 0.02). There was no corresponding interaction for aspirin use, possibly because of limited power.These data provide modest evidence that the C allele of COX-2 .8473 may interact with NSAIDs to reduce risk for hormone receptor positive breast cancer.

PubMed ID: 17181859 Exiting the NIEHS site

MeSH Terms: Alleles; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use*; Aspirin/therapeutic use*; Breast Neoplasms/epidemiology; Breast Neoplasms/genetics*; Breast Neoplasms/prevention & control*; Case-Control Studies; Cyclooxygenase 2/genetics*; Female; Genotype; Humans; Polymorphism, Single Nucleotide; Receptors, Steroid; Risk

Back
to Top